HRR Mutation Testing in mPC
How might advances in testing for homologous recombination repair (HRR) gene mutations benefit your patients with metastatic castration-resistant prostate cancer (mCRPC)? Put new innovations into practice with this resource, designed to help you identify people who may be eligible for life-prolonging treatments. Get the updates you need to know, from expert perspectives on overcoming barriers to equitable testing to the latest highlights from major congresses:
Podcast: Expert exchanges – HRR in mPC
In the latest episode of our expert series, Colin Pritchard joins host Alicia Morgans to discuss liquid vs tissue biopsy in mPC.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
of interest
are looking at
saved
next event